Herzinsuffizienz – eine mitochondriale Dysfunktion

Zusammenfassung

Die ATP-Synthese der Kardiomyozyten kann bei Herzinsuffizienz um bis zu 30 % reduziert sein. Daher scheint die Optimierung des Energiestoffwechsels der Herzmuskelzellen ein ursächlicher Ansatz zur Prävention und Therapie der Herzinsuffizienz zu sein. Die mitochondriale ATP-Synthese stellt dabei die Schlüsselfunktion dar, für die eine optimale Versorgung mit verschiedenen Mikronährstoffen limitierend ist. Die frühzeitige Diagnose eines Nährstoffmangels, der über eine mitochondriale Dysfunktion zum myokardialen Energiedefizit führen kann, ist somit ein wichtiger Faktor für die Prognose des Patienten mit Herzinsuffizienz.

Schlüsselwörter

Herzinsuffizienz - mitochondriale Dysfunktion - Energiestoffwechsel - Nährstoff

• Literatur

• 1 Afsarmanesh N. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J 2006; 152: 1077-1083
• 2 Alehagen U et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation. Int J Cardiol 2012; May 22 [Epub ahead of print]
• 3 Allard ML, Jeejeebhoy KN, Sole MJ. The management of conditioned nutritional requirements in heart failure. Heart Fail Rev 2006; 1: 75-82
• 4 Aquilani R, Viglio S, Iadarola P et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol 2008; 101: 104E-10E
• 5 Azuma J. Usefulness of taurine in chronic congestive heartfailure. Jpn Circ J 1992; 52: 95-99
• 6 Belardinelli R, Mucaj A, Lacalaprice F et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006; 27: 2675-2681
• 7 Ferrari R. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79-91
• 8 de Lorgeril M, Salen P, Accominotti M et al. Dietary and blood antioxidants in patients with chronic heart failure. Insights into the potential importance of seleniumin heart failure. Eur J Heart Failure 2001; 3: 661-669
• 9 Folkers K, Langsjoen P, Langsjoen PH. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Commun 1992; 182: 247-253
• 10 Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82: 901-904
• 11 Ge K, Yang G. The epidemiology of selenium deficiency in the etiological study of endemic diseases in China. Am J Clin Nutr 1993; 57 (Suppl. 02) 259S-263S
• 12 Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res 2007; 77: 334-343
• 13 Horwich TB. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008; 156: 1170-1176
• 14 Ingwall JS, Weiss RG. Is the failing heart energy starved?. Circ Res 2004; 95: 135-145
• 15 Khatta M, Alexander BS, Krichten CM et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000; 132: 636-640
• 16 Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82: 4240-4244
• 17 Masumura Y. Myocardial free carnitine and fatty acylcarni-tine levels in patients with chronic heart failure. Jpn Circ J 1990; 54: 1471-1476
• 18 Molyneux SL, Florkowski CM, George PM et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 2008; 52: 1435-1441
• 19 Munkholm H. Coenzyme Q10 treatment in serious heart failure. Bio Factors 1999; 9: 285-289
• 20 Murray AJ, Edwards LM, Clarke K. Mitochondria and heart failure. Curr Opin Clin Nutr Metab Care 2007; 10: 704-711
• 21 Pfister R. Plasma vitamin C predicts incident heart failure in men and women in European Prospective Investigation into Cancer and Nutrition-Norfolk prospective study. Am Heart J 2011; 162: 246-253
• 22 Rauchhaus M. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-1940
• 23 Regitz V. Metabolic alterations in end-stage heart failure. J Clin Chem Clin Biochem 1990; 28: 611-617
• 24 Sander S, Coleman CI, Patel AA et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12: 464-472
• 25 Serati AR. L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology 2010; 116: 178-182
• 26 Sheeran FL, Pepe S. Energy deficiency in the failing heart: linkingincreased reactive oxygen species and disruption of oxidative phosphorylation rate. Biochem Biophys Acta 2006; 1757: 543-552
• 27 Shimon I. Improved left ventricular function after thiamine supplementation. Am J Med 1995; 98: 485-490
• 28 Sica DA. Loop diuretic therapy, thiamine balance, and heart failure. Congest Heart Fail 2007; 13: 244-247
• 29 Smithline HA. Thiamine for the treatment of acute decompensated heart failure. Am J Emerg Med 2007; 25: 124-126
• 30 Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000; 3: 417-424
• 31 Tsutsui H. Mitochondrial oxidative stress and heart failure. Intern Med 2006; 45: 809-813
• 32 Weber KT et al. Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium. Cardiovasc Res 2009; 81: 500-508
• 33 Witte KK et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005; 26: 2238-2244
• 34 Zhang M, Shah AM. Role of reactive oxygen species in myocardial remodeling. Curr Heart Fail Rep 2007; 4: 26-30
• 35 Zittermann A et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 2003; 41: 105-112